BRIEF—FDA approves Palforzia for younger patients

The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.

Aimmune Therapeutics’ Palaforzia has been approved by the FDA since January 2020 for initiation of treatment in individuals ages four through 17 years with a confirmed diagnosis of peanut allergy with up-dosing and maintenance in individuals four years of age and older.

Those who take Palforzia must continue to avoid peanuts in their diets. A Risk Evaluation and Mitigation Strategy (REMS) is in place for Palforzia to mitigate the risk of anaphylaxis associated with Palforzia, which includes elements to assure safe use., which includes elements to assure safe use.